Skip to main content
TDSPHARM Co., Ltd. logo

TDSPHARM Co., Ltd. — Investor Relations & Filings

Ticker · 464280 ISIN · KR7464280007 KO Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2024-08-05 Capital/Financing Update
Country KR South Korea
Listing KO 464280

About TDSPHARM Co., Ltd.

http://tdspharm.gobizkorea.com/

TDSPHARM Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Transdermal Drug Delivery Systems (TDDS), where active ingredients are absorbed through the skin. The company focuses on creating safe and effective medicinal products through dedicated R&D efforts. Its product portfolio includes a variety of TDDS-based items such as medical cataplasmas, plasters, and patches for applications like pain relief and antibiotic delivery. In addition to its core pharmaceutical business, TDSPHARM also develops and manufactures Over-The-Counter (OTC) medicines and cosmetic products, aiming to provide a wide selection of accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by TDS Pharm. It details amendments to a previously submitted registration statement, including updated financial data (preliminary earnings) and risk factors. This is a formal regulatory filing required for public offerings in South Korea, which falls under the category of a Securities Registration Statement. Given the provided categories, 'Regulatory Filings' (RNS) is the most appropriate classification for this type of formal regulatory document.
2024-08-05 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 98% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment (정정신고) filed by TDS Pharm. It details changes to the public offering schedule, including demand forecasting, subscription dates, and payment dates, as well as updates to investment risk factors and financial information. This is a formal regulatory filing related to a capital raising/IPO process. According to the provided definitions, this fits best under 'Regulatory Filings' (RNS) as it is a formal amendment to a registration statement, which is a standard regulatory disclosure document.
2024-07-17 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 98% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment (정정신고) filed by TDS Pharm. It details changes to the public offering schedule, including demand forecasting, subscription dates, and payment dates, as well as updates to investment risk factors and offering procedures. This is a formal regulatory filing related to a capital raising/IPO process. Since it is a specific regulatory filing document (not an announcement of a report), it falls under the 'Regulatory Filings' category.
2024-07-02 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) of South Korea by '주식회사 티디에스팜' (TDS Pharm Co., Ltd.) on June 21, 2024. It details the offering of 1,000,000 shares, investment risks, and business information. In the context of Korean financial filings (DART system), a '증권신고서' is a formal regulatory filing required for public offerings, which falls under the 'Regulatory Filings' category as it is a primary disclosure document for capital raising.
2024-06-21 Korean
감사보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'TDS Pharm' (주식회사 티디에스팜) for the fiscal year ending December 31, 2023. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an annual report (10-K) which typically includes management discussion and analysis (MD&A) and broader corporate disclosures, nor is it a simple earnings release. Therefore, it is classified as an Audit Report. FY 2023
2024-04-03 Korean
감사보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'TDS Pharm' (주식회사 티디에스팜) for the fiscal year 2022. It includes the independent auditor's opinion, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an earnings release or a summary report, and it is not an announcement of a report (RPA). Therefore, it falls under the 'Audit Report' category. FY 2022
2023-04-05 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.